Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM12EYR)

• Drug Name: R348 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Psoriasis vulgaris	EA90	Terminated	[1]

• Cross-matching ID:
  PubChem CID: 68254
  CAS Number: CAS 529-21-5
  TTD Drug ID: DM12EYR

Molecule-Related Drug Atlas

Drug(s) Targeting Janus kinase 3 (JAK-3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tofacitinib	DMBS370	Rheumatoid arthritis	FA20	Approved	[2]
Ritlecitinib	DMYKNME	Alopecia areata	ED70.2	Approved	[3]
ASP-015K	DMZ1UOI	Psoriasis vulgaris	EA90	Phase 3	[4]
VX-509	DM2U3MX	Rheumatoid arthritis	FA20	Phase 2/3	[5]
Cerdulatinib	DMSCR2H	B-cell lymphoma	2A86	Phase 2	[3]
ATI-501	DMTY6OF	Alopecia	ED70	Phase 2	[6]
ATI-502	DM8NODR	Alopecia	ED70	Phase 2	[7]
TD-8236	DMTOMJN	Asthma	CA23	Phase 2	[8]
ALXN2075	DM1BSD8	Non-hodgkin lymphoma	2B33.5	Phase 1/2	[9]
SNA-125	DM8L1GJ	Atopic dermatitis	EA80	Phase 1	[3]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Janus kinase 3 (JAK-3)	TTT7PJU	JAK3_HUMAN	Inhibitor	[1]

References

• [1] Emerging drugs for psoriasis. Expert Opin Emerg Drugs. 2009 Mar;14(1):145-63.
• [2] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [3] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [4] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2049).
• [5] Selective JAK inhibitors in development for rheumatoid arthritis. Expert Opin Investig Drugs. 2014 Aug;23(8):1067-77.
• [6] Clinical pipeline report, company report or official report of Aclaris Therapeutics.
• [7] ClinicalTrials.gov (NCT03759340) ATI-502 Topical Solution for the Treatment of Alopecia Areata (AA), Alopecia Universalis (AU) and Alopecia Totalis (AT). U.S. National Institutes of Health.
• [8] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2023. Adis Insight
• [9] The Dual Syk/JAK Inhibitor Cerdulatinib Antagonizes B-cell Receptor and Microenvironmental Signaling in Chronic Lymphocytic Leukemia. Clin Cancer Res. 2017 May 1;23(9):2313-2324.